NOXXON Pharma N.V. (ALNOX.PA)
| Previous Close | 0.2978 |
| Open | 0.2820 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2802 - 0.3292 |
| 52 Week Range | 0.2100 - 0.7100 |
| Volume | |
| Avg. Volume | 700,631 |
| Market Cap | 21.652M |
| Beta (5Y Monthly) | 2.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2190 |
| Earnings Date | Apr. 28, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- Business Wire
NOXXON Announces Enrolment of First Patient in the Expansion of the NOX-A12 Phase 1/2 Trial in Brain Cancer
BERLIN, December 07, 2021--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces today that the first patient was enrolled in an expansion arm of the GLORIA clinical trial of NOX-A12 in MGMT unmethylated brain cancer (glioblastoma, GBM). The patient has received their first week of treatment of NOX-A12 (600 mg/week) and the VEGF inhibitor bevacizumab combined with
- Business Wire
NOXXON Summarizes Essential Points From Key Opinion Leader Event on NOX-A12 & Radiotherapy Combination in Brain Cancer Held on November 23, 2021 With Dr Frank A. Giordano
BERLIN, December 02, 2021--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), hosted a Key Opinion Leader (KOL) event with Frank A. Giordano, M.D. on November 23, 2021, to discuss the combination of NOX-A12 and radiotherapy in brain cancer (glioblastoma, GBM). Dr. Giordano is Director and Chair of the Department of Radiation Oncology, University Hospital Bonn, Germany, a
- Business Wire
NOXXON: New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer Presented at the Society for Neuro-Oncology Annual Meeting 2021
BERLIN, November 22, 2021--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announces that new data from the ongoing Phase 1/2 GLORIA trial with NOX-A12 and radiotherapy in brain cancer (glioblastoma multiforme, GBM) were presented at the Society for Neuro-Oncology (SNO) Annual Meeting. The presentation was held by Frank A. Giordano, M.D., Director
